Skip to main content

Month: September 2025

NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC

Treatment remained well-tolerated with consistent injection feasibility in 103 heavily pre-treated patients with R/M-HNSCC naïve or resistant to anti-PD-1 63% (26/41) disease control rate (“DCR”) and 37% (15/41) objective response rate (“ORR”) in evaluable anti-PD-1 naïve patients per RECIST 1.1 74% (37/50) DCR and 32% (16/50) ORR in evaluable anti-PD-1 resistant patients per RECIST 1.1 15.5 months median Overall Survival (“mOS”) in evaluable anti-PD-1 naïve patients 11.4 months mOS in evaluable anti-PD-1 resistant patients Investigators concluded that these promising results warrant further exploration in randomized controlled trialsData presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th PARIS and CAMBRIDGE, Mass., Sept. 29,...

Continue reading

Altai Announces Sale of Cessford Oil Wells Property

TORONTO, Sept. 29, 2025 (GLOBE NEWSWIRE) — Altai Resources Inc. (TSXV: ATI) (“Altai” or the “Company”) announced today that it has sold its ownership of a 50% working interest in the oil wells property located in Cessford, Alberta, comprised of 4 oil wells (the “Cessford Oil Wells Property”), to the owner of the other 50% working interest, and the property’s operator, Canadian Natural Resources Limited (“CNRL”), for a net liability settlement of $50,674 (the “Net Liability Settlement”), which is comprised of the sale of the asset portion and the settlement of the liability portion. The Net Liability Settlement has been paid for by an inter-bank cash transfer from the Company to CNRL. The Net Liability Settlement represents a gain of $111,728 (or approximately 69%) over the Company’s decommissioning liability, net of the carrying...

Continue reading

AtlasClear Holdings Announces Fourth Quarter and Full Year Fiscal 2025 Financial Results and Corporate Update

– Earnings call scheduled for Tuesday, September 30, 2025, at 8:30 a.m. ET – Over $43 million in debt converted, reducing De-SPAC liabilities by more than 80% – Stockholders’ Equity is up over $43 million from Year End 2024 – Third correspondent clearing customer signed to onboard – Extended contract to acquire Commercial Bancorp of Wyoming – Leadership team strengthened with additions of CFO/GC Sandip Patel and Independent Director Steven Carlson TAMPA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) — AtlasClear Holdings, Inc. (NYSE American: ATCH) (“AtlasClear Holdings” or the “Company”) announced today its financial results for the fourth quarter and full fiscal year ended June 30, 2025. The Company will host its earnings call on Tuesday, September 30, 2025, at 8:30 a.m. Eastern Time. “We are excited...

Continue reading

INVO Fertility to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

SARASOTA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) — INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 5:00 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.webinar.net/arwq56W8612. The webcast will also be available for...

Continue reading

Beneficient Reports Results for Fourth Quarter & Fiscal Year Ended March 31, 2025

Transformative Year Reduced Operating Costs, Launched New Products and Improved Financial Position Beneficient is Positioned to Capitalize on Adjacent Market Growth Opportunities DALLAS, Sept. 29, 2025 (GLOBE NEWSWIRE) — Beneficient (NASDAQ: BENF) (“Ben” or the “Company”), a technology-enabled platform providing exit opportunities and primary capital solutions and related trust and custody services to holders of alternative assets through its proprietary online platform, AltAccess, today reported its financial results for the fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. Commenting on the fiscal 2025 results, Beneficient management said: “Fiscal 2025 marked a turning point for Beneficient as we streamlined operations and continued to execute on our business plan. Following fiscal year end, we continued to make...

Continue reading

NewtekOne, Inc. Declares Dividend on Series B Preferred Shares

BOCA RATON, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) — NewtekOne, Inc. (“the Company”) (NASDAQ: NEWT) has declared a dividend on the Company’s outstanding 8.500% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B (the “Preferred Shares”) in the amount of $9.44 per Preferred Share, or $0.2361 per depositary share, which is equivalent to 1/40th of the dividend on the Preferred Shares, payable on October 1, 2025 to holders of record as of September 29, 2025. This initial dividend payment on the Preferred Shares is pro-rated for the initial dividend period from the date of the issuance of the Preferred Shares on August 20, 2025. About NewtekOne, Inc. NewtekOne®, Your Business Solutions Company®, is a financial holding company, which along with its bank and non-bank consolidated subsidiaries (collectively, “NewtekOne”),...

Continue reading

Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) — Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today reported its financial results for its fiscal year ended June 30, 2025, and provided recent business updates. “It is an exciting time for Neuphoria as we rapidly approach topline data from our AFFIRM-1 Phase 3 study of BNC-210 in social anxiety disorder, which is anticipated early in the fourth quarter of this year,” said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Neuphoria....

Continue reading

Precision Optics Reports Fourth Quarter and Fiscal Year 2025 Financial Results

Conference Call Scheduled for today, September 29, 2025, at 5:00pm ET Company introduces fiscal year 2026 Revenue and Adjusted EBITDA guidance Company appoints new Chief Operating Officer GARDNER, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) — Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, announced operating results on an unaudited basis for its fourth quarter and fiscal year 2025 for the period ended June 30, 2025. Q4 2025 Financial Highlights (3 Months Ended June 30, 2025):Revenue was $6.2 million, a new quarterly record, compared to $4.7 million in the same quarter of the previous fiscal year and compared to $4.2 million in the most recent sequential quarter, representing growth of approximately 48%. Production...

Continue reading

Concorde International Group Reports 11% Year-over-Year Revenue Growth to $6.0 million for H1 of 2025

Gross profit increased 30% year-over-year to $1.9 million for H1 2025, compared to $1.5 million for the same period last year Gross margin increased 450 basis points to 31.5% for H1 2025, compared to 27.0% for the same period last year SINGAPORE, Sept. 29, 2025 (GLOBE NEWSWIRE) — Concorde International Group Ltd. (NASDAQ: CIGL) (“Concorde” or the “Company”), an integrated security services provider that combines physical manpower and innovative technology to deliver effective security solutions, today announced financial results and provided a business update for the first half of 2025 (H1 2025) ended June 30, 2025. H1 2025 Financial HighlightsRevenue increased by approximately 11%, to approximately $6.0 million for H1 2025, compared to approximately $5.4 million for H1 2024 Gross profit increased by approximately 30% to $1.9...

Continue reading

Magnera Announces Strategic Exit from Argentina as Part of Project CORE Transformation

CHARLOTTE, N.C., Sept. 29, 2025 (GLOBE NEWSWIRE) — As part of its ongoing transformation initiative (Project CORE), Magnera today announced a key step in optimizing operations and aligning resources with long-term growth priorities. Effective immediately, production will halt and operations at the company’s Pilar, Argentina site will begin winding down. The company will continue to fulfill pre-existing commitments out of the site and ensure continuity for customers during this transition. The closure is part of Project CORE (Capacity Optimization and Resource Efficiency), a company-wide program introduced in Magnera’s most recent earnings release. Project CORE is designed to streamline Magnera’s global footprint, enhance operational agility, and deliver greater value to customers and partners. “This was not a decision taken lightly,”...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.